The leading resource for comprehensive insight and
intelligence on the global psychedelics industry.
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic healthcare industry.
A data and insights platform for the psychedelic healthcare industry.
The Psychedelics as Medicine Report positions organisations in front of regulators, researchers and investors.
Previous partners include @COMPASSPathway, @CybinInc and @FilamentHealth.
To be included in the fourth edition, please contact [email protected]
$CMPS $CYBN $FH
'Regulators, legislators, physicians, therapists—pretty much everyone...—has some fear. I used to feel that way too until I started looking closely at the data.'
Mason Marks, Senior Fellow at @Harvard_Law, spoke to @BMJ_latest on psilocybin's potential:
Psilocybin: a revolution in psychedelic medicines in the US?
As a flurry of US states approve psilocybin for medicinal use, Joanne Silberner asks whether the most carefully st...
‘This new centre aims to accelerate the integration of innovative models of care, including psilocybin therapy into the @NHSuk.'
@COMPASSPathway's CEO, Kabir Nath, spoke with @MetroUK on initiatives for publicly funded psychedelic healthcare: $CMPS
How psychedelics and tranquilisers could be the new therapy
The future is bright, but there is a barrier to these drugs and it is inertia.
In 2023, medical practitioners in Alberta will be able to apply for a license to conduct psychedelic-assisted therapy.
It is hoped regulatory reform at the state-level will instigate federal legalisation: via @CBCNews
Alberta to be 1st province to regulate psychedelics for therapy, government says | CBC News
Alberta will become the first Canadian jurisdiction to regulate the use of psychedelic drugs for people in therapy, the province announced Wednesday.
🍄Colorado’s Natural Medicine Health Act
🇬🇧The UK’s psychedelic healthcare ecosystem
⚕️The Economist explores psychedelic medicine
Read more in Issue 101 of The Psychedelics Newsletter: https://bit.ly/3fLjj0H
Join over 25,000 investors, academics and operators who receive the latest news on the psychedelic science and healthcare industry. Straight to your inbox once a week.
Gain unparalleled market intelligence and insights from thought-leaders and industry experts, identifying lucrative opportunities for investors, operators and regulators.